secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0001387131-22-011124
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix Q3 net loss widens to $29M on higher R&D spend; cash at $140M
-------------------------------------------------------------------

- Net loss $29.0M ($0.69/sh) vs $18.5M ($1.60/sh) in Q3 2021; share count rose to 41.9M from 11.6M.
- Cash and equivalents $140M at Sept 30, 2022, down from $178.7M at Dec 31, 2021.
- R&D expenses $22.2M in Q3 2022 vs $13.1M in Q3 2021, driven by clinical and manufacturing costs.
- Raised $15.0M in Oct 2022 via private placement of Series A/B convertible redeemable preferred stock.
- Interim data from Phase 3 fibromyalgia and Phase 2 Long COVID TNX-102 SL studies expected in Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000138713122011124/0001387131-22-011124-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000138713122011124/tnxp-8k_110722.htm
  HTML page:      https://secwatch.observer/filing/0001387131-22-011124

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer